Mark Landreneau
About the Teacher
Why study with them?
Mark Landreneau received his MD from Columbia University College of Physician and Surgeons and subsequently completed a neurology residency and neurocritical care fellowship at Yale-New Haven Hospital. He has worked as faculty in the department of neurology at Yale University and now maintains a practice at Centered focusing on neuropsychiatric disorders in addition to his neurohospitalist practice at Yale.
He has significant experience and skill treating life threatening injuries of the nervous system including brain injuries that cause disorders of consciousness. He has written multiple articles and book chapters on severe strokes, brain death, and novel treatments for brain and spinal injuries. Over time he developed a particular interest in mood disorders related to neurological illness as well as mood disorders more generally, particularly in the context of neuroplastogens and psychedelics.
He brings a background using multimodal monitoring in the ICU–integrating noninvasive and invasive monitoring such as EEG, advanced neuroimaging, and novel neurophysiological monitors. Using insights from recent clinical trials and basic science studies on psychedelics, he has a deep interest in integrating the neurophysiology of psychedelics with psychotherapy in order to maximize treatment effects from this powerful class of medications.
At the moment, his focus is on ketamine assisted therapy, learning and integrating cutting edge developments in the field into his practice. His approach is informed by an emerging neuroscientific model of circuits and networks, viewing this as inseparable from subjective experience, where humanistic traditions have studied the mind for thousands of years.
He has significant experience and skill treating life threatening injuries of the nervous system including brain injuries that cause disorders of consciousness. He has written multiple articles and book chapters on severe strokes, brain death, and novel treatments for brain and spinal injuries. Over time he developed a particular interest in mood disorders related to neurological illness as well as mood disorders more generally, particularly in the context of neuroplastogens and psychedelics.
He brings a background using multimodal monitoring in the ICU–integrating noninvasive and invasive monitoring such as EEG, advanced neuroimaging, and novel neurophysiological monitors. Using insights from recent clinical trials and basic science studies on psychedelics, he has a deep interest in integrating the neurophysiology of psychedelics with psychotherapy in order to maximize treatment effects from this powerful class of medications.
At the moment, his focus is on ketamine assisted therapy, learning and integrating cutting edge developments in the field into his practice. His approach is informed by an emerging neuroscientific model of circuits and networks, viewing this as inseparable from subjective experience, where humanistic traditions have studied the mind for thousands of years.
